Azienda USL Nord Ovest   Report issue

Academic/Hospital Phase 3
Founded: Pisa Italy (2015)

Organization Overview

First Clinical Trial
2019
NCT03848039
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Alessandro Ghelardi | Az. USL Toscana Nord Ovest | L'Azienda USL Nord Ovest

Active Ingredients

Drugs in Phase 3 Trials (1)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma in Situ (Phase 3)

Cervical Intraepithelial Neoplasia (Phase 3)

Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1